Aldehyde dehydrogenases (ALDHs) comprise a broad superfamily of metabolic enzymes, with 19 gene groups identified in the human genome. These genes participate in diverse biological processes, including the detoxification of exogenous and endogenous aldehydes. In recent years, ALDHs have garnered increasing attention due to their association with stem cell-related characteristics in a wide range of hematopoietic malignancies and solid tumors. ALDH1B1, an isoform and member of the ALDH superfamily, is aberrantly expressed in multiple cancers. For instance, ALDH1B1 is dysregulated in pancreatic cancer (particularly pancreatic ductal adenocarcinoma, PDAC), where it drives tumor progression through multiple mechanisms: maintaining stemness (e.g., activating Notch and Wnt/β-catenin pathways), metabolic reprogramming (acetaldehyde metabolism, reducing toxic aldehyde accumulation while generating NADPH to sustain redox balance), activating oncogenic pathways (e.g., inducing WNT signaling to promote epithelial-mesenchymal transition and enhance invasiveness), and conferring therapy resistance. ALDH1B1 overexpression induces significant changes in cell morphology, proliferation rates, and clonogenic efficiency, thereby contributing to lung adenocarcinoma development. In esophageal carcinogenesis, three genome-wide significant loci in heterozygotes include ALDH1B1, which exhibits a genome-wide significant interaction with rs671, potentially increasing the risk of esophageal cancer (a classic alcohol-associated disease). Domestic studies have shown that miR-761 can target and suppress ALDH1B1 to inhibit osteosarcoma cell proliferation, migration, and invasion. Furthermore, ALDH1B1 promotes colorectal cancer progression by regulating cancer stemness and key oncogenic signaling pathways. This article elucidates the mechanistic roles of ALDH1B1 in various malignancies, with a particular focus on its specific interactions in the development and progression of colorectal cancer. Notably, ALDH1B1 promotes colorectal carcinogenesis by mediating unique metabolic reprogramming processes. On one hand, ALDH1B1 maintains intracellular redox balance through acetaldehyde oxidation, creating a favorable metabolic microenvironment for cancer stem cells. On the other hand, its involvement in retinoic acid metabolism dysregulation aberrantly activates key oncogenic pathways such as Wnt/β-catenin signaling. Furthermore, ALDH1B1 enhances the glycolytic switch (the Warburg effect) by modulating mitochondrial energy metabolism, thereby supplying the bioenergetic and biosynthetic precursors required for rapid tumor cell proliferation. These metabolic regulatory mechanisms synergize with ALDH1B1’s role in sustaining cancer stem cell properties, collectively forming a multidimensional network through which ALDH1B1 drives colorectal cancer progression. A deeper understanding of the logical relationship between ALDH1B1-mediated metabolic regulation and carcinogenesis will provide a more comprehensive insight into its role in various cancers, particularly colorectal cancer, and offer a theoretical foundation for developing novel ALDH1B1-targeted therapeutic strategies. However, more detailed molecular mechanisms, clinical relevance, and potential therapeutic value require further experimental and clinical validation.
This study aimed to analyze factors influencing home non-invasive positive pressure ventilation (NPPV) adherence in patients with chronic obstructive pulmonary disease (COPD), and to construct and evaluate the clinical effectiveness of a behavioral intervention program based on the Health Belief Model (HBM). The intervention program was developed through questionnaire surveys and semi-structured interviews with 200 patients, followed by Delphi expert consultations. Subsequently, a 3-month randomized controlled trial (RCT) was conducted to evaluate its efficacy, with the control group receiving conventional health guidance.Post-intervention, the intervention group demonstrated significantly higher total Health Belief Scale scores (4.2 ± 0.3 vs. 2.5 ± 0.4), improved NPPV behavioral adherence (32.4 ± 1.8 vs. 20.1 ± 2.5), and lower CAT scores (10.3 ± 2.1 vs. 20.5 ± 3.2) compared to the control group. Furthermore, blood gas analysis, 6-minute walk test results, and lung function indices were all significantly better in the intervention group (all P < 0.001). Behavioral intervention based on the Health Belief Model can effectively improve NPPV treatment adherence in stable COPD patients, enhance their quality of life, and improve physiological function, demonstrating significant clinical value for promotion.
Colorectal cancer (CRC) is a highly aggressive form of cancer that poses a significant threat to public health worldwide. The progression of this disease is primarily driven by metabolic changes, especially the disruption of lipid metabolism. Cancerous CRC cells proliferate uncontrollably and invade surrounding tissues due to abnormal modifications in fatty acid synthesis, lipid uptake, storage, and β-oxidation. These metabolic shifts are influenced by key oncogenic signaling pathways, such as the PI3K/AKT/mTOR pathway and the MYC transcriptional network, which also enhance interactions with the tumor microenvironment's stromal elements. Recent research suggests that targeting lipid metabolism through pharmacological means could offer substantial clinical benefits. This article provides a comprehensive analysis of the molecular mechanisms involved in the reprogramming of lipid metabolism in CRC development and assesses its potential for innovative therapeutic approaches.
This study aimed to conduct a pan-cancer analysis of WD40 Repeat-Containing SOCS Box Protein 1 (WSB1) through bioinformatics, detect its expression in lung adenocarcinoma (LUAD) tissues and adjacent normal tissues by immunohistochemistry (IHC), analyze its correlation with clinical indicators, and explore its diagnostic and prognostic value. We performed WSB1 bioinformatics analysis using data from multiple public databases (including TCGA, GTEx, HPA, CPTAC, etc.). IHC was used to detect the expression difference of WSB1 in LUAD tissues and adjacent normal tissues, followed by statistical processing and clinicopathological data analysis. Kaplan-Meier plotter was used to analyze the relationship between WSB1 expression and survival, and GO and KEGG pathway enrichment analyses were conducted to explore its functions. WSB1 was differentially expressed between various cancers and normal tissues. Specifically, WSB1 mRNA levels were downregulated in LUAD, while protein levels were significantly upregulated (P < 0.05). WSB1 expression was negatively correlated with LUAD distant metastasis (P < 0.05) and promoter methylation, and positively correlated with overall survival (OS), tumor immunity, and PDCD1. The genetic variation frequency of WSB1 was >4% (3.18% in LUAD), and there was no correlation with gender, age, etc. IHC validation (80 LUAD samples and 80 adjacent normal tissues) confirmed that WSB1 expression in LUAD tissues was significantly higher than that in adjacent normal tissues. WSB1 is upregulated at the protein level in LUAD and serves as a potential prognostic marker. It correlates with tumor immunity/PDCD1 (as a marker of immunotherapy sensitivity) and promoter methylation (through epigenetic regulation), and its abnormal expression may be caused by high-frequency mutations.
Astragalus membranaceus is a traditional Chinese medicine widely used in the management of diabetes mellitus. Its major bioactive constituents—astragalus polysaccharides (APS), astragaloside IV (AS-IV), and flavonoids—demonstrate significant anti-diabetic properties. This review summarizes current evidence on the therapeutic potential and molecular mechanisms of A. membranaceus and its major components in treating T2DM and its complications. Literature was retrieved from six databases: PubMed, Science Direct, Academic Journals, Web of Science, Research Gate, and Google Scholar. Search terms included “type 2 diabetes mellitus”, “Astragalus membranaceus”, “polysaccharides”, “saponins”, “flavonoids”, and their combinations. Bioactive compounds from A. membranaceus modulate glucose metabolism and ameliorate insulin resistance (IR). APS restores glucose homeostasis via the PI3K/Akt and AMPK pathways, alleviates endoplasmic reticulum (ER) stress, and regulates gut microbiota. It also confers protection against diabetic cardiomyopathy, nephropathy, cognitive dysfunction, bladder dysfunction, and ulcers through anti-inflammatory, antioxidative, and pro-autophagic activities. AS-IV improves dysregulated glucolipid metabolism by modulating the AMPK/mTOR, ERK1/2, and NF-κB pathways. Flavonoids exert renoprotective effects by mitigating mitochondrial dysfunction and inflammation. A. membranaceus and its bioactive constituents provide a multitargeted strategy to alleviate T2DM and its complications by regulating metabolic, inflammatory, and oxidative stress pathways. However, poor oral bioavailability remains a major limitation for clinical translation. Recent advances in structural modifications and novel delivery systems offer promising avenues to overcome this challenge. As an alternative or adjunctive therapy, A. membranaceus holds considerable potential in diabetes management.